Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic.

Adam Gray (D-CA), and Neal Dunn (R-FL) introduced the Protecting Patient Access to Cancer and Complex Therapies Act. This ...

The IRA instructs Medicare to negotiate based on several factors, including the drug’s price and effectiveness compared to its competitors, and the negotiation is constrained by a ceiling price ...

The negotiation, informed by confidential data from manufacturers and analysis by the Centers for Medicare and Medicaid Services, will result in a maximum fair price for each drug, which will be ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era ...

Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...

In all, Medicare spent about $50.5 billion on these 10 medications, or 20% of its Part D prescription drug costs, between June 1, 2022 and May 31, 2023, the Biden adminsitration said.

Medicare drug price negotiation: Innovation chilled ... HHS estimates that the first round of price negotiations for the 10 drugs covered under Medicare Part D would have saved $6 billion if these ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Medicare soon will start something it hasn't done in its 58-year history: Negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

The drug has seen its list price increase 108 percent since it was introduced in 2013—but it started with the "nosebleed-level" price of $90 a pill, which equates to $130,000 for annual treatment.

Medicare drug price negotiation will help Black and Latino people, women, LGBTQI+ people, disabled people, and others who often have trouble affording medications.